Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing

Ioanna Sevastou, Gareth Pryce, David Baker, David L. Selwood

1 Department of Medicinal Chemistry, UCL Wolfson Institute for Biomedical Science, London, WC1E 6BT, United Kingdom, 2 Neuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, E1 2AT, United Kingdom

Abstract

Multiple sclerosis (MS) is a debilitating immune-mediated neurological disorder affecting young adults. MS is primarily relapsing-remitting, but neurodegeneration and disability accumulate from disease onset. The most commonly used mouse MS models exhibit a monophasic immune response with fast accumulation of neurological damage that does not allow the study of progressive neurodegeneration. The chronic relapsing and secondary progressive EAE (pEAE) Biozzi ABH mouse model of MS exhibits a reproducible relapsing-remitting disease course that slowly accumulates permanent neurological deficit and develops a post-relapsing progressive disease that permits the study of demyelination and neurodegeneration. RNA sequencing (RNAseq) was used to explore global gene expression in the pEAE Biozzi ABH mouse. Spinal cord tissue RNA from pEAE Biozzi ABH mice and healthy age-matched controls was sequenced. 2,072 genes were differentially expressed (q < 0.05) from which 1,397 were significantly upregulated and 675 were significantly downregulated. This hypothesis-free investigation characterised the genomic changes that describe the pEAE mouse model. The differentially expressed genes revealed a persistent immunoreactant phenotype, combined with downregulation of the cholesterol biosynthesis superpathway and the LXR/RXR activation pathway. Genes differentially expressed include the myelination genes Slc17a7, Ugt8A and Opalin, the neuroprotective genes Sprr1A, Osm and Wisp2, as well as genes identified as MS risk factors, including RGs14 and Scap2. Novel genes with unestablished roles in EAE or MS were also identified. The identification of differentially expressed novel genes and genes involved in MS pathology, opens the door to their functional study in the pEAE mouse model which recapitulates some of the important clinical features of progressive MS.
Introduction

Multiple sclerosis (MS) is a central nervous system disease that primarily affects young adults. MS has a median survival expectancy of 40 years after diagnosis [1], while patients start accumulating significant levels of disability early in disease progression, which adds a substantial burden to their everyday lives. MS is an immune-mediated disorder, characterised by demyelination and neurodegeneration [2]. The clinical presentation of MS is most commonly relapsing-remitting, but can also be primary progressive, where neurodegeneration and disability accumulate from disease onset. Over time relapsing remitting MS acquires a secondary progressive phenotype, with pathology accumulating between relapses [3]. Neurological symptoms in MS reflect focal inflammatory demyelinating lesions in the central nervous system that affect saltatory conduction in the affected sites [2]. Accumulating neurological disability is accompanied by disabling symptoms such as spasticity, tremor and muscle stiffness [4].

The most commonly used mouse model for the study of MS is the experimental autoimmune encephalomyelitis (EAE) model. This model has been extensively used in research, primarily in C57BL/6 mice immunised with myelin oligodendrocyte glycoprotein (MOG) peptide 35–55. These mice exhibit a monophasic immune response with fast accumulation of neurological damage, rendering them as perhaps not the most suitable EAE model to study progressive neurodegeneration [5]. The SJL mouse strain is a strain that develops relapsing-remitting disease following active immunisation, and is thus useful for the study of immune responses that more closely compare to the human disease [6]. However, the severe clinical disease and the low incidence of relapse in these mice makes it hard to study accumulating neurological disability. Thus existing mouse models do not always address the neurodegenerative processes that underlie primary or secondary progressive MS. The neurodegenerative component of MS remains a challenge and is currently untreated [7], in contrast to significant advances in controlling relapsing remitting MS, which responds to immunosuppressive treatments [8–10]. Although the adaptive immune response drives relapsing disease and is sensitive to immune modifying drugs that act in the periphery to prevent new lesion formation and active attacks [7, 9], progressive neurodegenerative disease is probably driven by innate inflammatory responses within the CNS, which are insensitive to current peripheral immunomodulatory drugs in both progressive EAE and MS [7, 9, 11]. Additionally, it has been demonstrated that neurodegeneration can persist beyond the elimination of clinical relapses in EAE [12], as occurs in relapsing MS also [8]. Therefore there is a need to develop novel neuroprotective therapeutic approaches to complement current immunomodulatory approaches. To address this challenge, the study of chronic progressive EAE models, where the underlying pathological chronic neurodegenerative mechanisms are present, is expected to provide valuable insight in disease pathophysiology and potential therapeutic targets.

The chronic relapsing and secondary progressive EAE Biozzi ABH mouse model of MS exhibits a reproducible relapsing-remitting disease course that slowly accumulates permanent neurological deficit, which is followed by progressive neurodegeneration and disability (pEAE), with associated residual signs of disease such as spasticity and tremor [13–16]. Histological studies of Biozzi ABH mouse spinal cord tissue reveal immune-mediated relapsing disease episodes that prime the CNS-microenvironment for persistent demyelination, gliosis, glial cell activation, axonal and neuronal loss [16, 17]. Thus, the pEAE mouse model permits the study of mechanisms involved in the accumulation of neurological damage. Treatment of neurodegeneration is likely to be critical in the treatment of progressive MS so this Biozzi ABH mouse chronic model may provide a platform where strategies for neuroprotection and neurorepair can be evaluated.
In this study we used RNA sequencing (RNAseq) to explore gene expression in the spinal cord of the post-relapsing secondary progressive pEAE Biozzi ABH mouse model. During the post-relapsing pEAE disease stage the spinal cord is characterised by widespread demyelination, astrocytic gliosis, microglial activation and little to none immune infiltration [12, 17]. This hypothesis-free investigation of global gene expression aimed to characterise the genomic changes that describe this pEAE mouse model and to generate the complete transcriptome of the chronic, neurodegenerative EAE state. By studying the individual genes that were differentially expressed, as well as the pathways that were differentially regulated, we were able to better characterise the immunological, neurodegenerative and remyelinating components of the disease, as well as to propose genes and processes worth investigating further as potential therapeutic targets.

Materials and Methods

Animals

Adult (6–8 weeks), pathogen-free male Biozzi ABH mice were bred at Queen Mary University of London. Methods of housing and other reporting elements relevant to the ARRIVE guidelines have been reported previously [18]. All procedures were approved by the Queen Mary University of London Animal Welfare and Ethical Review Body and the United Kingdom Government Home Office Inspectorate. These studies where performed under Licence from the UK Home Office and conformed to the United Kingdom Animals (Scientific Procedures) Act 1986 for the use of animals in research and Directive 2010/63/EU.

pEAE Induction

pEAE was induced in Biozzi ABH mice as described previously [18]. Briefly, young adult mice were injected subcutaneously with 1 mg freeze-dried mouse spinal cord homogenate in Freund’s adjuvant on days 0 and 7. Animals developed relapsing-remitting episodes of limb paralysis with remission. Spasticity and slow deterioration of movement typically developed after 2–3 relapses, \( \sim 80–100 \) d post-induction [7, 9, 18]. Pathology in this model is largely restricted to the spinal cord [13], so animal spinal cords were sampled during remission from active paralytic episodes associated with hindlimb paralysis and weight loss [12, 17].

RNA Extraction and Sequencing

Three post-relapsing chronic pEAE animals were sacrificed following the development of spasticity and tremor, at least 3 months after disease induction and after at least 3 clinical attacks as indicated previously [19]. Three age-matched control mice that did not receive an injection with spinal cord homogenate in Freund’s adjuvant were also sacrificed. The spinal cord tissue was removed, snap-frozen in liquid nitrogen and stored at -80°C. Frozen tissue was disrupted in TRIzol Reagent on ice, using a rotor-stator homogeniser. Following 5 min incubation at room temperature, chloroform was added to the samples, which were shaken, left to rest and then centrifuged at 12000 g for 15 minutes. The resulting upper aqueous phase was washed with 70% ethanol, mixed well and loaded on an RNeasy column. Thereafter the Qiagen RNeasy Mini Kit protocol was followed to extract and purify mRNA. mRNA integrity was assessed by microfluidic capillary electrophoresis using the Agilent 2100 Bioanalyzer. All samples had a 260/280 ratio > 1.8 with RNA integrity number (RIN) > 9. RNA samples were processed and sequenced at the UCL Genomics facility (UCL Institute of Child Health) using the Illumina NextSeq 500 platform. Library preparation was performed using the TruSeq Stranded Total RNA Library Prep Kit. 43 bp paired-end sequencing was performed and approximately
18–25 million reads were obtained per sample. The dataset can be found in the Gene Expression Omnibus (GEO), accession number GSE78996.

**Data Analysis**

The FASTQ files generated for each sample were aligned to the UCSC *Mus musculus* mm10 reference genome using the TopHat2 software (Illumina). Downstream analysis of these alignments was performed using Cufflinks software (Illumina). Cufflinks computes normalised fragments per kilobase of exon per million fragments mapped (FPKM) which reflect the expression levels of each mRNA molecule [20]. The reads were mapped to a total of 23,352 genes and 30,608 transcripts. To calculate *p* values, Cufflinks uses the Cuffdiff 2 algorithm that estimates expression at transcript-level resolution and controls for variability across replicate libraries. The Cuffdiff 2 statistical algorithm is described in depth in [21]. The Cuffdiff 2 algorithm statistically analysed gene expression and produced a list of differentially expressed genes in the pEAE tissue samples. The statistical analysis resulted in *p* values corrected for multiple testing with a default false discovery rate (FDR) of *q* < 0.05.

To generate a heatmap for comparison of gene expression between all samples the UCL Genomics facility (UCL Institute of Child Health) R-based pipeline was used. To compare the lists of differentially expressed genes in pEAE with other published sets of genes, publically available Venn analysis software was used (http://bioinfogp.cnb.csic.es/tools/venny/index.html).

**Ingenuity Pathway Analysis**

Ingenuity pathway analysis (IPA, Ingenuity Systems®, www.ingenuity.com) was used to identify biological and molecular networks differentially regulated in the pEAE model. IPA is a source of gene-interaction based pathway analysis including canonical pathways and a knowledge database based on scientific findings. Statistically significant differentially expressed genes at least 2-fold upregulated or downregulated were imported and analysed in the IPA database. Based on the direct or indirect connectivity of genes as disclosed in the literature, genes were mapped onto biological pathways and disease networks. Fisher’s exact test was performed to validate assignment of a biological function or disease to a network. Canonical pathway analysis was based on the identification of molecular pathways that are most significant for the dataset.

**Results**

**Differential Gene Expression Levels**

The spinal cord tissue RNA sequencing resulted in approximately 18–25 million reads per sample, which were aligned on the *Mus musculus* mm10 reference genome. This resulted in the identification of 23,352 annotated genes. Downstream statistical analysis of gene expression between control and pEAE samples (Cuffdiff) resulted in 14,373 genes successfully tested for differential expression (test status OK). Genes that were omitted from the analysis included genes with insufficient alignments for testing (NOTEST), too shallowly sequenced genes (LOWDATA), or genes with too many fragments aligned on the locus (HIDATA). It should be noted here that two genes, *Mbp* and *Plp1*, were not successfully tested due to a HIDATA return. These two genes are constituents of myelin, thus their involvement in this EAE model cannot be overlooked. They both had O FPKM in the control mice, but very high average fragment numbers (7939.56 and 2639.63 respectively) in the pEAE samples. Thus even though these genes are not included in the statistical analysis and the Ingenuity pathway analysis, they are
included in the lists of highly upregulated genes. From the mapped genes, 2,072 were differentially expressed with a default false discovery rate (FDR) of \( q < 0.05 \) (\( p < 0.0072 \)). More specifically, 1,397 genes were significantly upregulated (\( q < 0.05 \)) and 675 genes were significantly downregulated (\( q < 0.05 \)) (S1 and S2 Tables). The differential gene expression in the pEAE samples compared with the control samples is visualised in Fig 1A. The MA plot presents the ratio of FPKM expression values between the two conditions. All 14,373 genes are presented in the plot with differentially regulated genes highlighted in colour. The volcano plot (Fig 1B) presents the 14,373 genes, with genes with FDR < 0.05 (\( p < 0.0072 \), \( -\log p < 2.1426 \)) visualised in colour. In Fig 1B the statistically significant genes with a larger that 2-fold change in expression are presented in red and are the genes selected for further analysis. The heatmap in S1 Fig demonstrates the hierarchical clustering within the three control and three pEAE spinal cord samples which represents the differential expression of significantly regulated genes between the control and pEAE groups.

### Differential Gene Expression Analysis

The list of highly upregulated genes with a fold change of more than 16 (\( \log_2 > 4 \)) reveals a number of genes with established roles in inflammatory processes, such as antigen processing and presentation, cell chemotaxis and cell adhesion (see S1 Table). This reveals a sustained inflammatory response in the spinal cord of the post-relapsing pEAE model, consistent with sustained microglial activity that remains following relapsing disease induced by the adaptive immune response [9, 12]. These findings are in line with the histological spinal cord studies during the progressive remitting stage of this EAE model, which have shown that the extensive immunoglobulin deposition and infiltration of macrophages, CD4+ T lymphocytes, B lymphocytes and leucocytes described during relapses is greatly diminished [13, 16] and the remitting spinal cord tissue is characterised by widespread demyelination, astrocytic gliosis and persistent low grade microglial activation [9, 12, 13, 17].

Additionally, a number of highly upregulated genes are genes involved in non-inflammatory biological functions, for example cell differentiation, proliferation, or ion transport. This list of genes is presented in Table 1. The Gene Ontology biological processes that are implicated in neurodegeneration, remyelination and related functions for each gene are also listed in Table 1. Some genes with cell adhesion properties may also be implicated in regenerative, remyelinating processes so they are included in the list. Associations with chronic EAE processes, differentiation, de/remyelination, neurodegeneration and neuroprotection are also referenced in Table 1.

The list of most significantly downregulated genes with a fold change of more than 4 (\( \log_2 > 2 \)), reveals that no genes are directly involved in inflammatory processes. Most of the genes downregulated are involved in the cholesterol biosynthesis and metabolism superpathway. The list of the downregulated genes and their possible involvement in pEAE is presented in Table 2. The Gene Ontology biological processes that are implicated in neurodegeneration, remyelination and related functions for each gene are also listed, as well as associations with chronic EAE processes, differentiation, de/remyelination, neurodegeneration and neuroprotection.

### Gene Network Construction

The gene network construction performed using the IPA platform aimed at creating a visual tool to assess connections between differentially expressed genes. The direct or indirect connectivity of genes as disclosed in the literature allows the assessment of connections between any two given genes. A network was constructed for the upregulated genes with \( >3 \)-fold increase (Fig 2). A large number of functional direct and indirect connections can be seen...
Fig 1. Identification of differentially expressed genes. (A) MA plot representing the ratio of FPKM expression values between chronic relapsing secondary progressive EAE samples and control samples plotted against their average. All 14,373 genes are plotted with significantly regulated genes (q < 0.05) plotted in red. (B) Volcano plot presenting the 14,373 genes, with genes over the significance cut off at p < 0.0072 (-log p < 2.1426) plotted in grey. The statistically significant genes with >2-fold change in expression are plotted in red.

doi:10.1371/journal.pone.0157754.g001
Table 1. Most significantly upregulated genes (>16 fold change) with non-immunological functions.

| Entrez Gene | Entrez Name                          | log₂ fold change | p value   | Gene ontology processes associated with EAE                                                                 | Association with chronic EAE processes, differentiation, de/remyelination, neurodegeneration, neuroprotection |
|-------------|--------------------------------------|------------------|-----------|---------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Mbp         | myelin basic protein                  | inf              | N/A       | Myelination                                                                                                   | Myelin constituent. Highly upregulated during oligodendrocyte differentiation [22].                           |
| Pip1        | proteolipid protein (myelin) 1        | inf              | N/A       | Myelination                                                                                                   | Myelin constituent. Highly upregulated during oligodendrocyte differentiation [22].                           |
| Mmp12       | matrix metallopeptidase 12            | inf              | 5.00E-05  | Positive regulation of epithelial cell proliferation involved in wound healing                                | Extracellular protease expressed in active macrophages in MS lesions [23]. Involved in the pathogenesis of Theiler’s murine encephalomyelitis, induces demyelination and neurotoxicity [24]. |
| Mcoln3      | mucolipin 3                           | inf              | 5.00E-05  | Auditory receptor cell differentiation, ion transport                                                          | Transient receptor potential channel (TRPML3) involved in endocytosis [25], localized to lysosomes and initiates neutralised lysosome exocytosis [26]. |
| Atp6v0d2    | ATPase, H+ transporting, lysosomal V0 subunit D2 | inf              | 5.00E-05  | ATP hydrolysis coupled proton transport                                                                       | Regulator of bone formation [27], no identified role.                                                        |
| Gpnmb       | glycoprotein (transmembrane) nmb      | 7.09385          | 5.00E-05  | Cell adhesion                                                                                                 | Upregulated in Lewis rat EAE [28] and in an amyotrophic lateral sclerosis mouse model, proposed neuroprotective role [29]. |
| Wisp2       | WNT1 inducible signaling pathway protein 2 | 6.21785          | 5.00E-05  | Cell adhesion, cell growth regulation                                                                          | Promotes neurite outgrowth in ganglioside deficient mice [30].                                               |
| Plin4       | perilipin 4                           | 5.82633          | 5.00E-05  | Lipid storage regulation                                                                                        | Protein present in spinal cord, involved in lipid droplet storage [31].                                      |
| Steap4      | STEAP family member 4                 | 5.37493          | 5.00E-05  | Ion transport                                                                                                 | Involved in osteoclast differentiation [32], no identified role.                                             |
| Ms4a7       | membrane-spanning 4-domains, subfamily A, member 7 | 5.34068          | 0.0001    | Unknown                                                                                                       | No identified role. Associated with late-onset Alzheimer’s disease [33].                                     |
| Gm4841      | predicted gene 4841                   | 5.20993          | 0.0007    | Unknown                                                                                                       | No identified role.                                                                                           |
| Cybb        | cytochrome b-245, beta polypeptide     | 5.02298          | 5.00E-05  | Immune response, ion transport                                                                                | Superoxide generating enzyme Nox2, implicated in microglial induced neurodegeneration [34].                   |
| Gpr65       | G-protein coupled receptor 65         | 4.94688          | 0.026     | G-protein coupled receptor signaling pathway                                                                  | Proton sensing TDAG8 receptor, involved in osteoclast regulation [35].                                        |
| Ch25h       | cholesterol 25-hydroxylase             | 4.91766          | 5.00E-05  | Cholesterol metabolism                                                                                        | Proposed susceptibility gene for Alzheimer’s disease [36]. Proinflammatory enzyme, ch25h deletion attenuates EAE [37]. |
| Sprr1a      | small proline-rich protein 1A          | 4.60697          | 0.0026    | Keratinocyte differentiation                                                                                   | Protein expressed after neuronal injury, involved in neuronal regeneration processes [38–40].               |
| Ppl         | perilipin                             | 4.55594          | 0.0026    | Unknown                                                                                                       | Abundant in the brain, opioid receptor interacting protein [41], no identified role.                           |
| Xdh         | xanthine dehydrogenase                 | 4.4114           | 5.00E-05  | Cell differentiation/apoptosis                                                                                 | Xanthine oxidase, the metabolic product of xanthine dehydrogenase, implicated in EAE pathogenesis, axonal and myelin loss [42]. |
| Wfnc17      | WAP four-disulfide core domain 17     | 4.38813          | 5.00E-05  | Unknown                                                                                                       | Anti-neuroinflammatory microglial protein [43].                                                             |
| Osm         | oncostatin M                          | 4.30594          | 0.0026    | Immune response, peripheral nervous system development                                                         | Upregulated in relapsing-remitting MS patients [44], protective against demyelination in the Cuprizone-induced demyelination model [45]. |
| Ms4a6d      | membrane-spanning 4-domains, subfamily A, member 6D | 4.26213          | 5.00E-05  | Unknown                                                                                                       | No identified role.                                                                                           |
| Rnf186      | ring finger protein 186               | 4.0977           | 0.0007    | Unknown                                                                                                       | No identified role.                                                                                           |
| Gpr114      | adhesion G protein-coupled receptor G5 | 4.09084          | 0.00345   | G-protein coupled receptor signaling pathway                                                                  | No identified role.                                                                                           |
| Tnfsf11     | tumor necrosis factor (ligand) superfamily, member 11 | 4.07763          | 0.00275   | Immune response, cell differentiation                                                                         | Osteoprotegerin ligand RANKL, important osteoclast differentiation factor [46]. Upregulated in MS patients [47, 48]. |

(Continued)
between membrane receptors that take part in the response and maturation processes of the immune system. Membrane receptors that belong to the major histocompatibility complex (H2 gene family receptors) group together since they directly interact with each other to orchestrate the autoimmune response. The constructed network illustrates the secreted chemokines Ccl3l3, Ccl4, and Ccl5 as hubs for multiple signaling connections. The connections between the upregulated members of the complement system, C2, C3, C4a/C4b, C1s, C1r, C1qa and C1qb are also depicted. Secreted Tnfsf11 that encodes for the receptor activator of nuclear factor kappa-B ligand (RANKL) also acts as a hub for multiple gene connections. RANKL, encoded by Tnfsf11, and its receptor RANK are central in regulating the function of dendritic cells and are critically involved in the maintenance of the number and function of CD4+CD25+ regulatory T cells [65, 66] (also see discussion). The multiple indirect connections of the putative neuroprotectant oncostatin M (Osm; see discussion) are also presented. Ptpn6, a tyrosine phosphatase with a role in inflammatory disease also forms many direct and indirect connections with the upregulated gene population.

The number of significantly downregulated genes that were involved in direct or indirect connections was small, so this allowed for the construction of a network using all the significantly downregulated genes with >2-fold increase (Fig 3). Interestingly but not surprisingly, the gene that formed the most connections in the network was Insig1, an endoplasmic reticulum receptor that plays an important role in the downregulation of cholesterol biosynthesis. The connections between Hmgcr and Cyp51a1, both enzymes involved in cholesterol biosynthesis (see discussion), and other downregulated genes are also depicted in the constructed network.

### Canonical Pathway Analysis

For the canonical pathway analysis, differentially expressed genes with a FDR of q < 0.05 and a fold change of at least 2 were selected (visualised in red in Fig 1B). This set of genes, comprising of 851 upregulated and 150 downregulated genes was imported into the Ingenuity pathway analysis platform (IPA, Ingenuity Systems®, www.ingenuity.com). The list of the 10 most significantly regulated canonical pathways is presented in Table 3. As expected from the gene analysis, the cholesterol biosynthesis superpathway was the most significantly downregulated pathway, with 17/27 genes downregulated. The LXR/RXR regulation pathway, a pathway emerging as a critical pathway in oligodendrocyte precursor cell (OPC) differentiation [67] was significantly regulated, with 23/121 genes upregulated and 4/121 genes downregulated. The rest of the significantly regulated canonical pathways were all upregulated pathways involved in immune processes, namely the dendritic cell maturation pathway, the T helper cell differentiation pathway, the pathway of hepatic fibrosis and hepatic stellate cell activation, the pathway of altered T and B cell signaling in rheumatoid arthritis, the acute phase response signaling pathway, the antigen presentation pathway, the complement system pathway and the pattern
recognition receptors in recognition of bacteria and viruses. All the above pathways in many instances overlap, with upregulated genes involved in tumour necrosis factor signaling, toll receptor signaling or antigen presentation processes involved in more than one upregulated pathway. The upregulation of pathways involved in immune processes further supports the presence of persistently activated microglia in pEAE mice.
Comparison between pEAE and Microarray EAE Studies

To dissect the unique molecular characteristics of the pEAE mouse model, its comparison with transcriptional studies of other EAE rodent models can provide valuable information about genes and pathways that may be similarly or differently regulated between different models. The comparison of the present pEAE study with other transcriptomic studies of EAE models proved difficult, since lack of publicly available data, especially from older studies, as well as differences in the methodology used, in animal species, strain and immunisation antigens selected, in most cases did not allow direct comparison of the studies. In absence of MOG-induced mouse EAE transcriptional data, the lists of differentially expressed genes from two EAE microarray studies re-analysed in a meta-analysis performed by Raddatz et al. [68] were selected to compare with the pEAE mouse data.

The first study was a MOG-induced relapsing EAE study performed on Dark Agouti rat spinal cord tissue, where healthy rats were compared to the acute, remitting and relapsing states of the disease [69]. The comparison of the differentially expressed pEAE genes with the differentially upregulated or downregulated genes in the different disease states revealed some overlap between the two models (Fig 4). In the relapsing disease stage a large percentage of genes overlapped with the pEAE gene dataset. This supports higher similarities between the relapsing...
EAE phenotype and the progressive phenotype. All the lists of different or common genes at all disease stages can be found in S3 Table.

The second study was a PLP-induced acute EAE study of spinal cord tissue performed in SJL/J mice [70]. The comparison of the two different mouse EAE models revealed some similarities in gene expression (Fig 5). Since this comparison was performed between the acute disease stage of a monophasic EAE mouse model and the progressive EAE model, the lists of unique pEAE genes are informative in regards to the nature of genes differentially regulated in the chronic disease phase. The lists of different or common genes upregulated and downregulated in the two mouse EAE models can be found in S4 Table.

**Comparison between pEAE and Other RNAseq EAE Studies**

RNAseq is a relatively new transcriptomic analysis technology and so far only very few RNAseq studies have addressed MS and EAE models. An advantage of RNAseq is that the very small amounts of RNA required allow the identification of the transcriptome of cellular populations rather than whole tissue. The single RNAseq study that investigated the whole transcriptome in an EAE mouse model was performed on spinal cord microglia and monocyte-derived macrophages isolated from different stages of MOG-induced EAE in C57BL/6 mice [71]. The differentially regulated canonical pathways identified in microglia and monocyte derived microglia during different disease stages were compared with our pEAE study. This
| Ingenuity Canonical Pathways                        | -log(p value) | Ratio | Down-regulated | No change | Up-regulated | No overlap with dataset | Molecules                                                                 |
|---------------------------------------------------|---------------|-------|----------------|-----------|--------------|------------------------|---------------------------------------------------------------------------|
| Superpathway of Cholesterol Biosynthesis           | 1.59E01       | 6.3E-01 | 17/27 (63%)    | 0/27 (0%) | 0/27 (0%)    | 10/27 (37%)            | HMGC51, NSDHL, ACAT2, FDPS, HMGCR, SC5D, MSMO1, LSS, SQLE, ID1, DHCR24, MKV, TM7SF2, HSD17B7, CYP51A1, MVD, DHCR7 |
| Dendritic Cell Maturation                          | 1.53E01       | 2.25E-01 | 2/169 (1%)     | 0/169 (0%) | 36/169 (21%) | 131/169 (78%)          | PLCB2, H-2-AHLA-DQA1, FCGR1A, TNFRSF1A, PIK3R5, PLCE1, TLR6, Fcer1GC, NFkBA1, TREM2, TLR4, IL23A, IRF6, HLA-DMA, STAT1, TYROBP, HLA-DRB5, HLA-DMB, IL1RL2, CD80, TLR2, CD86, IL33, LTB, HLA-DQB1, TNFRSF1B, MAP3K14, HLA-DOB, B2M, FCGR2A, PIK3CG, PLCG2, HLA-A, FCGR2B, IL1A, COL2A1, ICAM1, IKBK |
| T Helper Cell Differentiation                      | 1.48E01       | 3.58E-01 | 0/67 (0%)      | 0/67 (0%) | 24/67 (36%)  | 43/67 (64%)            | IL21R, TGFBI, TNFRSF1A, HLA-DQA1, HLA-DQB1, TNFRSF1B, IL6R, ICOSLg/LOC10273996, HLA-DOB, Fcer1GC, IL2RG, IL10RA, TGFBR2, IL10RB, HLA-DMA, STAT1, HLA-DRB5, STAT6, HLA-DMB, CD80, IL4R, Rorc, CD86, IL12RB1 |
| Hepatic Fibrosis / Hepatic Stellate Cell Activation | 1.31E01       | 1.94E-01 | 2/196 (1%)     | 0/196 (0%) | 36/196 (18%) | 158/196 (81%)          | TGFBI, TNFRSF1A, IL6R, TNFSF9, LBP, TNFSF13, IL10RA, TLR4, A2M, CCR5, IL1R1, STAT1, EDN1, IL1RL2, LTB, CCL5, TNFSF11, COL6A3, KDR, TNFRSF18, CD14, IGBPBP5, FGFO2, COL5A1, IGIF, IFG2, ATG, TGFBR2, COL2A1, CCL2, IL1A, IL4R, COL2A1, SERPINE1, FAS, COL13A1, ICAM1, HGF |
| Altered T Cell and B Cell Signaling in Rheumatoid Arthritis | 1.27E01       | 2.96E-01 | 1/81 (1%)      | 0/81 (0%) | 23/81 (28%)  | 57/81 (70%)            | TLR7, TNFSF11, TGFBI, HLA-DQA1, HLA-DQB1, TLR1, MAP3K14, TLR9, Fcer1GC, IL10RA, TLR4, A2M, CCR5, IL1R1, STAT1, EDN1, IL1RL2, LTB, CCL5, TNFSF11, COL6A3, KDR, TNFRSF18, CD14, IGBPBP5, FGFO2, COL5A1, IGIF, IFG2, ATG, TGFBR2, COL2A1, CCL2, IL1A, IL4R, COL2A1, SERPINE1, FAS, COL13A1, ICAM1, HGF |
| Acute Phase Response Signaling                     | 1.16E01       | 1.96E-01 | 1/168 (1%)     | 0/168 (0%) | 32/168 (19%) | 135/168 (80%)          | CBF, OSM, C3, SOCS3, TNFRSF1A, IL6R, LBP, C1R, NFkBIA, A2M, C4A/C4B, C2, IL1R1, VWF, ITIH2, IL33, CP, TNFRSF1B, RBP1, MAP3K14, SERPINA3, HMOX1, PIK3CG, OSMR, AGT, CEBPB, IL1A, FTL, SERPINE1, C1S, SERPING1, TTR, IKBK |
| Antigen Presentation Pathway                       | 1.16E01       | 4.32E-01 | 0/37 (0%)      | 0/37 (0%) | 16/37 (43%)  | 21/37 (57%)            | HLA-E, CD74, HLA-DQA1, NLR5C5, HLA-G, HLA-DQB1, B2M, TAP1, HLA-A, TAP2, HLA-DMA, HLA-DRB5, HLA-DMB, MR1, PSMB9, PSMB8 |
| LXR/RXR Activation                                 | 1.1E01        | 2.23E-01 | 4/121 (3%)     | 0/121 (0%) | 23/121 (19%) | 94/121 (78%)           | C3, TNFRSF1A, HMGCR, LBP, PON3, TLR4, C4A/C4B, LDLR, IL1R1, IL1RL2, IL33, MLYP, S100A8, SREBF1, TNFRSF1B, CD14, APOD, ABCA1, MSR1, AGT, LYZ, CCL2, IL2A, IL8, CYP51A1, APOE, TTR |
| Complement System                                  | 1.06E01       | 4.17E-01 | 0/36 (0%)      | 0/36 (0%) | 15/36 (42%)  | 21/36 (58%)            | ITGAM, CBF, C3, C1Qb, ITGAX, ITGB2, C1R, CFH, C3AR1, C1QA, C1QC, C4A/C4B, C2, C1S, SERPING1 |
| Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses | 1.04E01       | 2.18E-01 | 0/119 (0%)     | 0/119 (0%) | 26/119 (22%) | 93/119 (78%)           | OSM, TGFBI, C3, TLR1, PIK3R5, TLR9, C3AR1, C1QA, TLR4, SYK, IRF7, TLR6, TLR2, PTX3, TLR7, CCL5, C1QB, CASP1, PIK3CG, PLCG2, C1QC, PRKCD, NLRP3, IFIH1, IL1A, CLEC7A |

Table 3. Ten most significantly altered canonical pathways.

doi:10.1371/journal.pone.0157754.t003
Fig 4. Comparison of the differentially expressed pEAE genes with differentially expressed genes in MOG-induced EAE in Dark Agouti rats at different disease stages. (A) Venn diagrams of upregulated and downregulated pEAE genes compared with acute MOG-induced EAE. (B) Venn diagrams of upregulated and downregulated pEAE genes compared with remitting MOG-induced EAE. (C) Venn diagrams of upregulated and downregulated pEAE genes compared with relapsing MOG-induced EAE.

doi:10.1371/journal.pone.0157754.g004
Comparison allowed us to identify the microglial and macrophage pathways that overlap with our dataset. It also allowed us to isolate pathways that are not enriched in microglial lineage cells and that can be related to monocyte/microglial independent disease mechanisms such as T-cell mediated immune processes, neurodegeneration, demyelination and remyelination. All canonical pathways in our dataset with 3 or more genes identified within the pathway were compared with the canonical pathways regulated in pre-symptomatic and active EAE (clinical score 3) monocyte derived macrophages, as well as with pre-symptomatic and active EAE microglial derived macrophages. As seen in the Venn diagrams in Fig 6A the majority of the canonical pathways enriched in each macrophage population were common with the pEAE dataset while some pathways were unique for the macrophage populations (all data in S5 Table). The unique canonical pathways in the pEAE dataset were plotted on a Venn diagram (Fig 6B) to isolate the 71 canonical pathways consistently unique to our dataset between all comparisons (S6 Table).

**Comparison between Differentially Regulated Genes and MS Susceptibility Genes**

During the last years, genome-wide association studies (GWAS) and other large-scale genotyping projects have revealed that only a few common genetic variants exist that exert relatively large MS risk, all of which are located in the HLA (human leucocyte antigen) locus. The remainder of the genetic risk spectrum comprises of a number of susceptibility variants exerting much smaller effects. So far, 110 independent SNPs outside the HLA locus have been identified to contribute to MS risk [72, 73]. A comparison between the published MS susceptibility genes and the differentially regulated genes in the pEAE mouse spinal cord tissue could reveal genes of specific interest to MS that also contribute to EAE pathology. Hoppmann et al. [74] recently produced a list of 209 human genes mapped in proximity to the 110 MS susceptibility loci. This list of mapped genes was compared with our set of upregulated and downregulated genes to identify MS susceptibility genes that overlap with our dataset. 34/209 MS susceptibility genes were significantly upregulated in the pEAE gene dataset, and 4/209 MS susceptibility genes were downregulated (Fig 7). These 38 MS susceptibility genes are of particular interest since their involvement in pEAE can highlight common disease processes.
Fig 6. Comparison between the regulated pathways of the pEAE dataset with presymptomatic and active EAE (clinical score 3) monocyte derived macrophages, as well as with presymptomatic and active EAE microglial derived macrophages. (A) Venn diagrams of each comparison set. (B) Venn diagram of the unique canonical pathways regulated only in pEAE mice identified from the comparison of the chronic relapsing and secondary progressive EAE dataset with the macrophage populations.

doi:10.1371/journal.pone.0157754.g006
The aim of this RNAseq study was to transcriptionally characterise the pEAE Biozzi ABH mouse model, to identify genes and molecular processes that may be specifically regulated in the chronic progressive phase of this disease model and to identify novel MS targets. The spinal cord transcriptional analysis revealed that a persistent immune response underlies the disease with immune pathways and genes highly upregulated (S1 and S2 Tables, Table 3). Immune
pathways and responses established in EAE pathology are involved in the pEAE model, such as the dendritic cell maturation pathway, the T helper cell differentiation pathway, the antigen presentation pathway and the complement system. However, it is clear that the adaptive immune response driven by T cells that induces relapsing disease is reduced during progressive EAE, which is more associated with chronic microglial activation [9, 12, 17] as also appears to be the case in neurodegeneration in MS that is associated with chronic microglial activation [75]. Additionally, pathways and genes that seem to play an important role in the chronic disease progression were also revealed, such as the highly downregulated cholesterol biosynthesis and the RXR/LXR activation pathways. Genes that increase susceptibility to MS were found up- or downregulated in this model, providing insights into the relevance of this model for the study of MS processes.

Genes Involved in Cellular Differentiation

Remyelination is a frequent event in MS lesions [76]. Shadow plaques, which are completely remyelinated lesions, account for 10–20% of all lesions [77]. Remyelination was histopathologically described in pEAE mice [17] and characterises the secondary progressive phenotype of this disease model. Here, the remarkable upregulation of Mbp and Plp1 expression in the pEAE model confirms that active remyelination takes place during the progressive phase of the disease model. Mbp and Plp1 encode for myelin basic protein and proteolipid protein 1, both constituent proteins of the myelin membrane, with a documented upregulation during oligodendrocyte differentiation [22]. Remyelination in progressive EAE as well as MS is limited. The reduced ability for lesion remyelination has been attributed to neuronal loss, but also the inability of OPCs to switch from a proliferating and migrating phenotype to a differentiating one. Genes involved in myelination significantly downregulated in the pEAE transcriptome reveal significant clues to remyelination failure processes. Vesicle bound glutamate transporter (VGLUT1), encoded by Slc17a7 is an axon terminal glutamate transporter required in neuronal–OPC synapses to promote myelination processes [51, 52]. Slc17a7 downregulation in pEAE reflects how neurodegeneration may inhibit myelination processes. Ugt8a was significantly downregulated in the pEAE mouse. Ugt8a encodes for the enzyme ceramide glucosyltransferase, which is essential for galactosylceramide production and myelin integrity [57]. Opalin is a myelin membrane protein present in paranodal loops [60] which was also significantly downregulated in the pEAE mouse. These downregulated genes involved in myelination present as promising targets for new remyelination strategies.

Attention should also be drawn to some regulated genes involved in cellular differentiation processes with no identified role in EAE or MS. Smyd1 for example is a downregulated transcriptional regulator identified as a key factor in myogenic differentiation [64] but with no known role in EAE or MS. Another example of a highly upregulated gene is Mcoln3, that encodes a transient Ca\(^{2+}\) channel, (TRPML3), which is involved in auditory receptor cell differentiation in mice [78]. Recently TRPML3 emerged as a transient receptor potential channel (TRP) located in lysosomes responsible for lysosomal extrusion following their neutralisation by bacterial infection [59]. The involvement of Mcoln3 in lysosomal homeostasis could implicate it in autophagosomal processes that may be related to neurodegeneration. Another group of upregulated genes involved in cellular differentiation include the H\(^{+}\) transporting ATPase Atp6v0d2, the ion transporter Steap4, the proton sensing receptor Gpr65 (TDAG8) and the Nf-κB ligand RANKL, encoded by Tnfsf11 (tumour necrosis factor superfamily member 11), all involved in the regulation of osteoclast differentiation [27, 32, 35, 46]. The upregulation of osteoclast differentiation molecules may reflect defects in bone remodelling in pEAE and MS, or may reflect a yet unidentified involvement of this differentiation pathway in disease.
progression. It is interesting to note that RANKL is significantly upregulated in MS patient serum [47, 48]. RANKL and its receptor RANK have a critical role in regulating the function of dendritic cells and in maintaining the number and function of CD4+CD25+ regulatory T cells [65, 66]. The involvement of RANKL in T cell regulation in active EAE was demonstrated in a recent study where RANKL depletion prevented EAE development due to impaired T cell infiltration into the CNS [79]. Thus the upregulation of RANKL in our dataset and the upregulated protein levels in MS patient serum may reflect the involvement of RANKL in T cell regulation in EAE and MS.

Genes Involved in Neurodegeneration and Neuroprotection

Some genes upregulated in the pEAE model that are involved in immune processes have been reported to also be involved in neurodegenerative processes. Matrix metallopeptidase 12 (Mmp12) is expressed in macrophages but has also been involved in inducing demyelination and neurodegeneration before macrophage infiltration in Theiler’s murine encephalopathy [24]. Mmp12 was highly upregulated in pEAE highlighting the possibility that regulation of Mmp12 levels could have a neuroprotective effect. Reactive oxygen species generating enzymes such as Cybb, encoding for the superoxide-generating microglial enzyme Nox2 and xanthine dehydrogenase (Xdh) were also upregulated in pEAE. Both enzymes have been implicated in neurodegenerative processes [34, 42].

A gene with a well-documented role in neuroprotection was upregulated in the pEAE dataset. Sprr1a, the small proline-rich protein A1, is a protein involved in keratinocyte differentiation which is upregulated in neurons following experimental brain injury [38], and in sciatic nerve and spinal cord sensory neurons following axotomy [39]. Sprr1a promotes neuronal outgrowth and is expressed soon after neuronal injury. Thus the upregulation of this gene indicates the activation of a neuroprotective mechanism in the pEAE spinal cord and highlights a potential therapeutic avenue that deserves further investigation. The transient channel TRPML3, encoded by the Mcoln3 gene and also known as cornifin-A, is a channel involved in keratinocyte differentiation. An additional gene involved in keratinocyte complex formation, Ppl which encodes periplakin was also upregulated in the pEAE mouse. It is possible that Ppl may be part of the pathway that promotes axonal regeneration together with Sprr1A, so further investigation of the involvement of Ppl in neuroprotection would be of interest. Additional genes with neuroprotective roles were also upregulated in the pEAE mouse model. Oncostatin M, encoded by the Osm gene was found upregulated in the serum of a cohort of people with relapsing-remitting MS [44], while oncostatin treatment protected against demyelination in the Cuprizone-induced demyelination model [45]. Gpnnmb is a transmembrane glycoprotein also found upregulated in Lewis rat EAE [28] and in a mouse model of amyotrophic lateral sclerosis [29]. A neuroprotective in vitro role has been proposed [29]. In a ganglioside deficient mouse model Wisp2, a protein with cell adhesion and cell growth regulation properties upregulated in our dataset was also found to be neuroprotective and promote neurite outgrowth in vitro [30]. The upregulation of neuroprotective genes in the pEAE mouse model suggests that this model can be used to investigate neuroprotective pathways in the progressive disease stage.

The Cholesterol Biosynthesis Pathway

The cholesterol biosynthesis pathway was identified as the most significantly regulated canonical pathway in the Ingenuity pathway analysis (Table 3), with 17/27 genes assigned to this pathway significantly downregulated. Importantly, some of the cholesterol biosynthesis pathway genes, such as the genes encoding the cholesterol synthesising enzymes isopentenyl-diphosphate delta isomerase (Idi1), 3-hydroxy-3-methylglutaryl-coenzyme A synthase 1 (HMG-CoA
reductase, Hmgcs1), methylsterol monoxygenase 1 (Sc4mol), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr) and squalene epoxidase (Sqle) are in the list of the most significantly downregulated genes in this analysis (Table 2).

Significant downregulation of the cholesterol biosynthesis genes during relapsing disease has also been reported in MOG-induced EAE in Dark Agouti rats [69], as well as in the spinal cord of MBP-induced EAE in Lewis rats [28]. In contrast to the MOG-induced EAE study though, where only cholesterol biosynthesis genes were downregulated, in our model cholesterol transport genes were also downregulated, indicating downregulation of additional components of cholesterol metabolism in the pEAE model. HMG-CoA reductase, a cholesterol rate-limiting enzyme has also been found downregulated in people with MS [80]. In the dysmyelinating peroxisome-proliferator-activated receptor gamma coactivator 1 (PGC1α) knockout mouse model, brain cholesterol, its precursors, and the rate-limiting enzymes HMG-CoA synthase (Mcoln3) and HMG-CoA reductase (Hmgcr), were downregulated [52]. There are two possible mechanisms that may result in cholesterol biosynthesis downregulation in EAE. One mechanism may involve the presence of cholesterol at lesions due to the breakdown of the cholesterol-rich myelin membranes, leading to inhibition of its biosynthesising pathway and contributing to remyelination inhibition. Cholesterol negatively regulates the transcription of cholesterol biosynthesis genes [81]. Another mechanism involved in cholesterol biosynthesis downregulation involves the activation of the immune system. It was recently shown that metabolic factors involved in cholesterol biosynthesis are downregulated to promote the expansion and reorganisation of pro-inflammatory CD4+ Th17 cells in vivo [74].

The involvement of cholesterol synthesis rate-limiting enzymes in MS and EAE pathology is also highlighted by the fact that HMG-CoA inhibitors ameliorate EAE and MS relapses by inhibiting immune cell activation and migration through the blood-brain barrier [82]. Lovastatin and simvastatin are HMG-CoA inhibitors taken to clinical studies for relapsing remitting MS [83, 84]. However, more importantly, high dose simvastatin has recently been shown to inhibit neurogeneration in secondary progressive MS [85], which is a disease stage that is not typically responsive to immune activation or blockage of peripheral immune responses entering the brain [8]. The finding here that cholesterol biosynthesis pathways are highly dysregulated in pEAE, which is mostly unresponsive to peripheral immunomodulation, may support the value of HMG-CoA inhibitors in progressive MS and provide a tool for mechanistic studies to understand the neuroprotective effects of statins. The transcriptomic data available clearly indicate a downregulation of this pathway but further investigation is needed to determine the physiological consequences of this downregulation.

Additionally Ch25h, a gene involved in cholesterol metabolism, was upregulated in the pEAE mouse. Cholesterol 25-hydroxylase is involved in lipid metabolism, catalyses the formation of 25-hydroxycholesterol from cholesterol and represses cholesterol biosynthetic enzymes [86]. Thus its upregulation agrees with the preferential downregulation of the cholesterol biosynthesis pathway. Ch25h has also been proposed as a susceptibility gene for Alzheimer’s disease [36] and its deletion can significantly attenuate EAE disease course by limiting trafficking of pathogenic CD4+ T lymphocytes to the central nervous system [37]. Lastly a lipid storage regulator, Plin4 is upregulated in pEAE and with no identified role in EAE or MS pathology its potential role in cholesterol or LXR/RXR metabolism (see below) would be worth investigating.

The LXR/RXR Activation Pathway

The LXR/RXR activation pathway was also significantly regulated in the pEAE model with 23/121 genes involved in this pathway downregulated and 4/121 upregulated. Genes involved in
this pathway include Ttr (transthyretin), the most significantly downregulated gene in this study (Table 2), the HMG-CoA reductase gene, as well as the highly downregulated genes Sc4mol and Ldr. The liver X receptors (LXRs) and the retinoid X receptors (RXRs) are obligate heterodimers that form ligand-activated nuclear transcription factors that regulate lipid homeostasis, including cholesterol metabolism [87]. The LXR pathway is emerging as a critical pathway in oligodendrocyte precursor cell (OPC) differentiation [67]. It was found that the RXR-γ receptor was significantly upregulated in the regenerative phase of remyelination in a toxin-induced demyelination model in rats, while the LXR/RXR activation pathway was significantly regulated [67]. This positive regulation of remyelination is a promising pharmaceutical target. The suppression of the LXR/RXR activation pathway identified in the pEAE model, may contribute to the limited remyelination observed in this model and suggests that upregulation of relevant components of the LXR/RXR pathway may promote remyelination.

Interestingly and perhaps not surprisingly, the LXR/RXR activation pathway was also highly regulated in the transcriptomic analysis of T cells isolated from acute mouse EAE [74], implicating LXR/RXR signaling in immune cell responses. In addition to genes such as Srebf1, Hmgcr, or Cyp51a1 which are involved in cholesterol biosynthesis, genes such as Abca1, Srebf1 and Lpl which are involved in cholesterol transport were also found regulated in Th17 cells, as well as in our dataset, implicating cholesterol transport in the disease progression. mRNA levels of LXR-β were also found increased in MS patient peripheral blood mononuclear cells [88]. Additionally, combination of LXR and RXR or PPARγ and RXR agonists can inhibit microglial and astrocyte inflammatory responses in vitro and in EAE models [89–92]. LXR/RXR signaling provides promising therapeutic options in MS, but much is still unclear about the role of this signaling pathway in specific cell populations and different phases of disease progression. Transcriptomic analysis of acute and chronic models can help with the elucidation of LXR/RXR signaling in MS.

Transthyretin, encoded by the Ttr gene is associated with the LXR/RXR activation pathway and is highly downregulated in our dataset. Transthyretin transfers thyroxin from the blood to the brain, where thyroxin is essential for oligodendrocyte maturation [49]. Thus the low transcripts of transthyretin in EAE spinal cord may be one factor contributing to remyelination failure. Transthyretin is highly expressed in MS patient serum [93], suggesting that there may be a failure in transthyretin transfer from the blood to the CSF and the brain and that pharmacological enhancement of that pathway may increase thyroxin availability in the brain and spinal cord and promote remyelination in MS patients.

The pEAE Mouse Model Transcriptome Compared to Other EAE Models

The pEAE Biozzi ABH mouse model exhibits a reproducible relapsing-remitting disease accompanied by demyelination, gliosis, glial cell activation, axonal and neuronal loss, followed by a slowly accumulating permanent neurological deficit [16, 17], which was examined here. The pEAE mouse model has been used for the study of mechanisms involved in the accumulation of neurological damage. Genes and pathways relevant to MS pathology are identified in this model, but its comparison to other EAE models can provide a lot of information about genes and processes unique to this model or common with other progressive phenotypes. The comparison of pEAE with a MOG-induced relapsing EAE study in Dark Agouti rats during the acute, remitting and relapsing stages of the disease [69] revealed some similarities between the two models, and especially similarities between upregulated genes (Fig 4, S3 Table). 66% of the upregulated genes in the relapsing phase of the MOG-EAE model were common with the pEAE model, opposed to 42% in the acute phase and 33% in the remitting phase. This supports higher similarities between the relapsing EAE phenotype and the pEAE phenotype, as such
active inflammation and progressive lesions co-exist in progressive MS, although the equilibrium is shifted to chronic glial cell lesions [75]. A limitation of our study was that only tissue from the secondary progressive phase of the disease was studied. Additional studies of different disease stages of the pEAE mouse model would help identify the molecular pathways unique in the progressive stage, as well as give even more information regarding similarities and differences between relapsing-remitting EAE models. On the other hand, our study identified a larger number of differentially expressed genes in comparison to older microarray studies.

Another interesting subject for further investigation would be the identification of the transcriptome of the different cellular populations of the pEAE spinal cord. RNAseq analysis has made it possible to collect small amounts of RNA and perform transcriptomic analysis. The comparison of our study with an RNAseq study of the transcriptome of monocyte derived or resident CNS microglia [71] in MOG-induced EAE revealed a wealth of information about macrophage-specific pathways regulated in pEAE, as well as pathways uniquely identified in pEAE (Fig 6, S6 Table).

MS Susceptibility Genes Significantly Regulated in Progressive EAE

pEAE is an experimental autoimmune mouse model that recapitulates key pathological features of secondary progressive MS, such as demyelination, remyelination, gliosis, axonal and neuronal loss [17]. Genes significantly modulated in pEAE are involved in disease mechanisms that are similar to MS pathology. To identify molecules in pEAE that may point to molecular pathways specifically relevant to MS pathology, we compared the pEAE transcriptome with 209 MS susceptibility genes [74] and identified 39 significantly regulated genes that are MS susceptibility genes (Fig 7). This list of genes (Fig 7B) comprises of immune-related genes such as the ligand C3, the cell surface proteins Cd37, Cd48, Cd86, Fcrls, Ltrb, Vcam1, Ccde88b and the cytoplasmic proteins Coro1a, Ifi30, Plek, MertK and Dab2. Tnfaip3, Tnfrsf14, Tnfrsf1a and Traf3a are genes that are involved in the tumor necrosis factor signaling processes. TNF signaling is central to MS and EAE pathology. Thus it comes as no surprise that in the pEAE mouse model TNF was identified as the most significantly regulated upstream regulator in the IPA analysis (data not shown, available on request). The transcription factors Hhex, Irf8, Maf, Stat3, Zfp36l1, Zfp36l2 and the transcription regulators Ikzf1, Ptf1 Sp110 were also upregulated in pEAE and although most of them are involved in immune-pathway transcription, their careful investigation could reveal additional functions. Sox8, the only transcription factor in the list which was downregulated in the pEAE mouse, promotes cellular differentiation and has a possible role in nervous system development.

MS susceptibility genes regulated in the pEAE without a clearly identified role in MS include the non-voltage gated sodium channel Scnn1a, the solute carrier Slc44a2, the lysosomal cysteine protease Ctsb, the serine biosynthesis enzyme Phgdh, and the mitochondrial Hmgsc2, an enzyme which controls ketogenesis. The proton sensing receptor Gpr65, involved in osteoclast differentiation, which is one of the most upregulated genes in the pEAE mouse model is also an MS susceptibility gene. Iqgap1 is a scaffolding protein recognised as instrumental in cytoskeletal organisation and cell signaling [94]. Rgs14, a regulator of G protein signaling found upregulated in pEAE and although most of them are involved in immune-pathway transcription, their careful investigation could reveal additional functions. Sox8, the only transcription factor in the list which was downregulated in the pEAE mouse, promotes cellular differentiation and has a possible role in nervous system development.

Interestingly it is also recognised as a neuronal suppressor of long-term potentiation of synaptic transmission in the hippocampus [95]. The neuronal role of Rgs14 opens a question as to whether its upregulation in pEAE may involve neuronal processes. Quantification of Rgs14 levels in neuronal cells in MS or EAE will help to resolve this question. The same applies to Scap2, a gene with documented expression in both neurones and immune cells. Scap2 is a Src kinase-associated phosphoprotein involved in integrin-stimulated cytoskeleton rearrangement [96].
but it is also involved in neuronal differentiation [97]. A glioblastoma susceptibility locus, Phldb1 [98] was also present in the list of MS susceptibility genes downregulated in the pEAE mouse. The identification of these MS susceptibility genes in the pEAE mouse model opens the door to their functional study in a mouse model which recapitulates some of the important clinical features of MS.

Conclusion

The aim of this study was to transcriptionally characterise the progressive Biozzi ABH EAE mouse model in an unbiased manner and identify genes and disease processes that may be specific to this mouse model and that may recapitulate some of the MS features more adequately than other disease models. Importantly, genes specifically regulated in the chronic phenotype of EAE were identified and their role in the chronic disease phase as well as their potential as therapeutic targets can be studied further.

Supporting Information

S1 Fig. Heatmap of gene expression between samples. Heatmap of significantly regulated gene expression demonstrating the hierarchical clustering within the three control (1CTR - 3CTR) and three pEAE (1EAE – 3EAE) spinal cord samples (top dendrogram). The left hand side dendrogram demonstrates clustering between genes as predicted in the R algorithm. Scale: Yellow indicates high expression and red demonstrates low expression. (TIFF)

S1 Table. Significantly upregulated genes. (XLSX)

S2 Table. Significantly downregulated genes. (XLSX)

S3 Table. Comparison between gene expression in MOG EAE and pEAE. (XLSX)

S4 Table. Comparison between gene expression in EAE and pEAE. (XLSX)

S5 Table. Comparisons between pEAE pathways and Macrophage RNAseq pathways. (XLSX)

S6 Table. All unique pEAE pathways after comparison with Macrophage RNAseq. (XLSX)

Acknowledgments

The authors are grateful for the support of Canbex Therapeutics and the Technology Strategy Board UK/Innovate UK grant no. 25036-166159.

Author Contributions

Conceived and designed the experiments: IS DLS. Performed the experiments: IS GP DB. Analyzed the data: IS. Contributed reagents/materials/analysis tools: IS GP DB DLS. Wrote the paper: IS DB DLS.
References

1. Thompson AJ. Multiple sclerosis—a global disorder and still poorly managed. Lancet Neurol. 2008; 7 (12):1078–9. Epub 2008/11/15. S1474-422X(08)70246-1 [pii] doi: 10.1016/S1474-422X(08)70246-1 PMID: 19007729.

2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372(9648):1502–17. Epub 2008/10/31. S0140-6736(08)61620-7 [pii] doi: 10.1016/S0140-6736(08)61620-7 PMID: 18970977.

3. Weinschenker BG. The natural history of multiple sclerosis. Neurol Clin. 1995; 13(1):119–46. Epub 1995/02/01. PMID: 7739500.

4. Stevenson V, Gras A, Bardos J, Broughton J. The high cost of spasticity in multiple sclerosis to individuals and society. Multiple sclerosis. 2015. Epub 2015/01/28. 1352458514566416 [pii] doi:10.1177/1352458514566416 PMID: 25623252.

5. Kuerten S, Gruppe TL, Laurentius LM, Kirch C, Tary-Lehmann M, Lehmann PV, et al. Differential patterns of spinal cord pathology induced by MP4, MOG peptide 35–55, and PLP peptide 178–191 in C57BL/6 mice. APMIS. 2011; 119(6):336–46. Epub 2011/05/17. doi:10.1111/j.1600-0463.2011.02744.x PMID: 21699081.

6. Brown AM, McFarlin DE. Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab Invest. 1981; 45(3):278–84. Epub 1981/09/01. PMID:6792424.

7. Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D. Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Multiple sclerosis. 2011; 17(8):339–48. Epub 2011/04/05. 1352458511400476 [pii] doi:10.1177/1352458511400476 PMID: 21459808.

8. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Annals of neurology. 1999; 46(3):296–304. Epub 1999/09/11. PMID:10482259.

9. Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, et al. Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. Journal of neuroimmunology. 2005; 165(1–2):41–52. Epub 2005/06/09. S0165-5728(05)00133-5 [pii] doi:10.1016/j.jneuroim.2005.04.009 PMID: 15939483.

10. Giovannoni G, Comi G, Cook S, Rampahlan K, Rieckmann P, Soelberg Sorensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):416–26. Epub 2010/01/22. NEJMoa0902533 [pii] doi:10.1056/NEJMoa0902533 PMID: 20089960.

11. Compston A, Coles A. Multiple sclerosis. Lancet. 2002; 359(9313):1221–31. doi:10.1016/S0140-6736(02)08220-X PMID:11955556.

12. Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin RJ, Giovannoni G, et al. Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathol Commun. 2013; 1(1):84. Epub 2013/12/25. 2051-5960(13)00014-5 [pii] doi:10.1186/2051-5960-1-84 PMID:2373763.

13. Baker D, O'Neill JK, Gschmeissner SE, Wilcox CE, Butter C, Turk JL. Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. Journal of neuroimmunology. 1990; 28(3):261–70. Epub 1990/08/01. PMID:2373763.

14. Heremans H, Dillen C, Groenen M, Martens E, Billiau A. Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-gamma. Eur J Immunol. 1996; 26(10):2393–8. Epub 1996/10/01. doi: 10.1002/eji.1830261019 PMID: 8899351.

15. Al-Izki S, Pryce G, Giovannoni G, Baker D. Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography. Multiple sclerosis. 2015; 15(7):795–801. Epub 2009/05/26. 1352458509104594 [pii] doi:10.1177/1352458509104594 PMID: 19465448.

16. Jackson SJ, Lee J, Nikodemova M, Fabry Z, Duncan ID. Quantification of myelin and axon pathology during relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. J Neuropathol Exp Neurol. 2009; 68(6):616–25. Epub 2009/05/22. doi: 10.1097/NEN. 0b013e3181a41d23 PMID: 1946548.

17. Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, et al. An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. Journal of neuroimmunology. 2008; 201–202:200–11. Epub 2008/08/02. S0165-5728(08)00225-7 [pii] doi: 10.1016/j.jneuroim.2008.05.034 PMID: 18672298.

18. Al-Izki S, Pryce G, O'Neill JK, Butter C, Giovannoni G, Amor S, Baker D. Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse.
Multiple Sclerosis and Related disorders. 2012; 1(1):29–38. doi: 10.1016/j.msard.2011.09.001 PMID: 25876448

19. Baker D, Jackson SJ. Models of multiple sclerosis. ACNR 2007; 6(6):10–2.

20. Trapnell C, Roberts A, Goff L, Perte G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature protocols. 2012; 7(3):562–78. Epub 2012/03/03. nprot.2012.06.16 [pii] doi: 10.1038/nprot.2012.016 PMID: 22383036; PubMed Central PMCID: PMC3334321.

21. Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL, Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nature biotechnology. 2013; 31(1):46–53. doi: 10.1038/nbt.2450 PMID: 23222703; PubMed Central PMCID: PMC3693932.

22. Dugas JC, Tai YC, Speed TP, Ngai J, Barres BA. Functional genomic analysis of oligodendrocyte differentiation. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2006; 26(43):10967–83. doi: 10.1523/JNEUROSCI.2572-06.2006 PMID: 17065439.

23. Vos CM, van Haastert ES, de Groot CJ, van der Valk P, de Vries HE. Matrix metalloproteinase-12 is expressed in phagocytic macrophages in active multiple sclerosis lesions. Journal of neuroimmunology. 2003; 138(1–2):106–14. PMID: 12742660.

24. Hansmann F, Herder V, Kalkuhl A, Haist V, Zhang N, Schaudien D, et al. Matrix metalloproteinase-12 deficiency ameliorates the clinical course and demyelination in Theiler’s murine encephalomyelitis. Acta neuropathologica. 2012; 124(1):127–42. doi: 10.1007/s00401-012-0942-3 PMID: 2271152.

25. Noben-Trauth K. The TRPML3 channel: from gene to function. Advances in experimental medicine and biology. 2011; 704:229–37. doi: 10.1007/978-94-007-0265-3_13 PMID: 21290299.

26. Miao Y, Li G, Zhang X, Xu H, Abraham SN. A TRP Channel Senses Lysosome Neutralization by Pathogens to Trigger Their Expulsion. Cell. 2015; 161(6):1306–19. doi: 10.1016/j.cell.2015.05.009 PMID: 26027738; PubMed Central PMCID: PMC4458218.

27. Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nature medicine. 2006; 12(12):1403–9. doi: 10.1038/nm1514 PMID: 17128270.

28. Inglis HR, Greer JM, Comcombe PA. Gene expression in the spinal cord in female lewis rats with experimental autoimmune encephalomyelitis induced with myelin basic protein. PLoS one. 2012; 7(11):e48555. doi: 10.1371/journal.pone.0048555 PMID: 23139791; PubMed Central PMCID: PMC3491034.

29. Tanaka H, Shimazawa M, Kimura M, Takata M, Tsuruma K, Yamada M, et al. The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis. Scientific reports. 2012; 2:573. doi:10.1038/srep00573 PMID: 23417778.

30. Okhawa Y, Ohmi Y, Tajima O, Yamauchi Y, Furukawa K, Furukawa K. Wisp2/CCN5 up-regulated in the central nervous system of GM3-only mice facilitates neurite formation in Neuro2a cells via integrin-Akt signaling. Biochemical and biophysical research communications. 2011; 411(3):483–9. doi: 10.1007/s00018-012-1015-4 PMID: 23990467; PubMed Central PMCID: PMC3798475.

31. Heck MV, Azizov M, Stehning T, Walter M, Kedersha N, Auburger G. Dysregulated expression of lipid storage and membrane dynamics factors in Tia1 knockout mouse nervous tissue. Neurogenetics. 2012; 15(2):135–44. doi: 10.1007/s10048-014-0397-x PMID: 24659297; PubMed Central PMCID: PMC3994287.

32. Zhou J, Ye S, Fujiwara T, Manolagas SC, Zhao H. Steap4 plays a critical role in osteoclastogenesis in vitro by regulating cellular iron/reactive oxygen species (ROS) levels and cAMP response element-binding protein (CREB) activation. The Journal of biological chemistry. 2013; 288(42):30064–74. doi: 10.1074/jbc.M113.478750 PMID: 23990467; PubMed Central PMCID: PMC3798475.

33. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature genetics. 2011; 43(5):436–41. doi: 10.1038/ng.801 PMID: 21460841; PubMed Central PMCID: PMC3090745.

34. Surace MJ, Block ML. Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors. Cellular and molecular life sciences: CMLS. 2012; 69(14):2409–27. doi: 10.1007/s00018-012-1015-4 PMID: 22581365; PubMed Central PMCID: PMC3677079.

35. Hikiji H, Endo D, Horie K, Harayama T, Akahoshi N, Igarashi H, et al. TDAG8 activation inhibits osteoclastic bone resorption. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2014; 28(2):871–9. doi: 10.1096/fj.13-233106 PMID: 24221084.

36. Papaasistratopoulos A, Lambert JC, Wavrant-De Vrieze F, Wollmer MA, von der Kammer H, Streffer JR, et al. Cholesterol 25-hydroxylyase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease. Neuro-degenerative diseases. 2005; 2(5):233–41. doi: 10.1159/000090362 PMID: 16909003.
37. Chalmin F, Rochermon V, Lippens C, Clottu T, Sailer AW, Merkler D, et al. Oxyesters regulate encephalitogenic CD4(+) T cell trafficking during central nervous system autoimmunity. Journal of autoimmunity. 2015; 56:45–65. doi: 10.1016/j.jaut.2014.10.001 PMID: 25456971

38. Marklund N, Fulp CT, Shimizu S, Puri R, McMillan A, Strittmatter SM, et al. Selective temporal and regional alterations of Nogo-A and small proline-rich repeat protein 1A (SPRR1A) but not Nogo-66 receptor (NgR) occur following traumatic brain injury in the rat. Experimental neurology. 2006; 197(1):70–83. doi: 10.1016/j.expneurol.2005.08.029 PMID: 16321388; PubMed Central PMCID: PMC2849132.

39. Bonilla IE, Tanabe K, Strittmatter SM. Small proline-rich repeat protein 1A is expressed by axotomized neurons and promotes axonal outgrowth. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2002; 22(4):1303–15. PMID: 11850458.

40. Starkey ML, Davies M, Yip PK, Carter LM, Wong DJ, McMahon SB, et al. Expression of the regeneration-associated protein SPRR1A in primary sensory neurons and spinal cord of the adult mouse following peripheral and central injury. The Journal of comparative neurology. 2009; 513(1):51–68. doi: 10.1002/cne.21944 PMID: 19107756; PubMed Central PMCID: PMC3339497.

41. Feng GJ, Kellett E, Scoer CA, Wilde J, White JH, Milligan G. Selective interactions between helix VIII of the human mu-opioid receptors and the C terminus of periplakin disrupt G protein activation. The Journal of biological chemistry. 2003; 278(35):33400–7. doi: 10.1074/jbc.M305866200 PMID: 12810704.

42. Honorat JA, Kinoshita M, Okuno T, Takata K, Koda T, Tada S, et al. Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis. PloS one. 2013; 8(8):e71329. doi: 10.1371/journal.pone.0071329 PMID: 23951137; PubMed Central PMCID: PMC3738596.

43. Karlsetetter M, Walczak Y, Weigelt K, Ebert S, Van den Brulle J, Schwer H, et al. The novel activated microglia/macrophage WAP domain protein, AMWAP, acts as a counter-regulator of proinflammatory response. Journal of immunology. 2010; 185(6):3379–90. doi: 10.4049/jimmunol.0903300 PMID: 20709948.

44. Alikhani P, Alsahefsoul F, Shajarian M. Investigation of Oncostatin M protein expression in Iranian relapsing remitting multiple sclerosis patients. Multiple sclerosis and related disorders. 2014; 3(6):747. doi: 10.1016/j.msard.2014.09.172.

45. Janssens K, Maheshwari A, Van den Haute C, Baekelandt V, Stinissen P, Hendriks JJ, et al. Oncostatin M protects against demyelination by inducing a protective microglial phenotype. Glia. 2015. doi: 10.1002/glia.22840 PMID: 25921393.

46. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2):165–76. PMID: 9568710.

47. Alatab S, Maghbooli Z, Hossein-Nezhad A, Khosrofar M, Mokhtari F. Cytokine profile, Foxp3 and receptor activator of nuclear factor-kappaB ligand levels in multiple sclerosis subtypes. Minerva medica. 2011; 102(6):461–8. PMID: 22193377.

48. Kurban S, Akshechosoul F, Shajarian M. Investigation of Oncostatin M protein expression in Iranian relapsing remitting multiple sclerosis patients. Multiple sclerosis and related disorders. 2014; 3(6):747. doi: 10.1016/j.msard.2014.09.172.

49. Janssens K, Maheshwari A, Van den Haute C, Baekelandt V, Stinissen P, Hendriks JJ, et al. Oncostatin M protects against demyelination by inducing a protective microglial phenotype. Glia. 2015. doi: 10.1002/glia.22840 PMID: 25921393.

50. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2):165–76. PMID: 9568710.

51. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2):165–76. PMID: 9568710.

52. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2):165–76. PMID: 9568710.

53. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2):165–76. PMID: 9568710.

54. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2):165–76. PMID: 9568710.
55. Xiang Z, Valenza M, Cui L, Leoni V, Jeong HK, Brilli E, et al. Peroxisome-proliferator-activated receptor gamma coactivator 1 alpha contributes to dysmyelination in experimental models of Huntington's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2011; 31(26):9544–53. doi: 10.1523/JNEUROSCI.1291-11.2011 PMID: 21715619; PubMed Central PMCID: PMC3132810.

56. Mathews ES, Mawdsley DJ, Walker M, Hines JH, Pozzoli M, Appel B. Mutation of 3-hydroxy-3-methylglutaryl CoA synthase I reveals requirements for isoprenoid and cholesterol synthesis in oligodendrocyte migration arrest, axon wrapping, and myelin gene expression. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2014; 34(9):3402–12. doi: 10.1523/JNEUROSCI.4587-13.2014 PMID: 24573296; PubMed Central PMCID: PMC3935092.

57. Bosio A, Binczek E, Stoffel W. Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93(23):13280–5. PMID: 8917582; PubMed Central PMCID: PMC24084.

58. Marchesi S, Montani F, Defiorian G, D’Antuono R, Cuomo A, Bologna S, et al. DEPDC1B coordinates de-adhesion events and cell-cycle progression at mitosis. Developmental cell. 2014; 31(4):420–33. doi: 10.1016/j.devcel.2014.09.009 PMID: 25458010; PubMed Central PMCID: PMC4250264.

59. He M, Kratz LE, Michel JJ, Vallejo AN, Kelley RI, et al. Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. The Journal of clinical investigation. 2011; 121(3):976–84. doi: 10.1172/JCI42650 PMID: 21285510; PubMed Central PMCID: PMC3049385.

60. Yoshikawa F, Sato Y, Tohyama K, Akagi T, Hashikawa T, Nagakura-Takagi Y, et al. Opalin, a transmembrane sialylglycoprotein located in the central nervous system myelin paranodal loop membrane. The Journal of biological chemistry. 2008; 283(30):20830–40. doi: 10.1074/jbc.M801314200 PMID: 18490449; PubMed Central PMCID:PMC3258930.

61. Tsai LJ, Hsiao SH, Tsai LM, Lin CY, Tsai JJ, Liou DM, et al. The sodium-dependent glucose cotransporter SLC5A11 as an autoimmune modifier gene in SLE. Tissue antigens. 2008; 71(2):114–26. doi: 10.1111/j.1399-0039.2007.00975.x PMID: 18069935.

62. Nelissen K, Mulder M, Smets I, Timmermans S, Smeefts K, Ameelc M, et al. Liver X receptors regulate cholesterol homeostasis in oligodendrocytes. Journal of neuroscience research. 2012; 90(1):60–71. doi: 10.1002/jnr.22743 PMID: 21972082.

63. Duhamel-Clerin E, Villarroya H, Mehtali M, Lapie P, Besnard F, Gumpel M, et al. Cellular expression of an HMGCR promoter-CAT fusion gene in transgenic mouse brain: evidence for a developmental regulation in oligodendrocytes. Glia. 1994; 11(1):35–46. doi: 10.1002/glia.440110106 PMID: 8070893.

64. Li D, Niu Z, Qian Y, Wang Q, Li Q, et al. SMYD1, the myogenic activator, is a direct target of serum response factor and myogenin. Nucleic acids research. 2009; 37(21):7059–71. doi: 10.1093/nar/gkp773 PMID: 19783823; PubMed Central PMCID:PMC2790895.

65. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nature medicine. 2006; 12(12):1372. doi: 10.1038/nm1518 PMID: 17143270; PubMed Central PMCID: PMC2438345.

66. Totsuka T, Kanai T, Nemoto Y, Tomita T, Okamoto R, Tsuchiya K, et al. RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis. Journal of immunology. 2009; 182(10):6079. doi: 10.4049/jimmunol.0711823 PMID: 19414759.

67. Huang JK, Jarjour AA, Nait Oumesmar B, Kerninon C, Williams A, Krezel W, et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nature neuroscience. 2011; 14(1):45–53. doi: 10.1038/nn.2702 PMID: 21131950; PubMed Central PMCID: PMC4013508.

68. Raddatz BB, Hansmann F, Spitzbarth I, Kalkuhl A, Deschl U, Baumgartner W, et al. Transcriptomic meta-analysis of multiple sclerosis and its experimental models. PLoS one. 2014; 9(1):e86643. doi: 10.1371/journal.pone.0086643 PMID: 24475162; PubMed Central PMCID: PMC3903571.

69. Mueller AM, Pedre X, Mutschler S, Kleiter I, Couillard-Despres S, Aigner L, et al. Novel role for SLPI in MOG-induced EAE revealed by spinal cord expression analysis. Journal of neuroinflammation. 2008; 5:20. doi: 10.1186/1742-2094-5-20 PMID: 18501024; PubMed Central PMCID:PMC3903571.

70. Available: http://www.ebi.ac.uk/arrayexpress/ [Internet].

71. Lewis ND, Hill JD, Duchem KW, Stefanopoulos DE, Modis LK. RNA sequencing of microglia and monocyte-derived macrophages from mice with experimental autoimmune encephalomyelitis illustrates a changing phenotype with disease course. Journal of neuroimmunology. 2014; 277(1–2):26–38. doi: 10.1016/j.jneuroim.2014.09.014 PMID: 25270668.

72. International Multiple Sclerosis Genetics C, Beecham AH, Pat spies NA, Xi kara DK, Davis MF, Kemppinen A, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple...
sclerosis. Nature genetics. 2013; 45(11):1353–60. doi: 10.1038/ng.2770 PMID: 24076602; PubMed Central PMCID: PMC3832895.

73. International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011; 476(7359):214–9. doi: 10.1038/nature10251 PMID: 21833088; PubMed Central PMCID: PMC3182531.

74. Hoppmann N, Graetz C, Paterka M, Poisa-Beiro L, Larochelle C, Hasan M, et al. New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis. Brain: a journal of neurology. 2015; 138(4 Pt 4):902–17. doi: 10.1093/brain/awu408 PMID: 25665584.

75. Frischer JM, Weigand SD, Guo Y, Kale N, Parisi JE, Pirko I, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Annals of neurology. 2015; 78(5):710–21. doi: 10.1002/ana.24497 PMID: 26239536; PubMed Central PMCID: PMC4623970.

76. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain: a journal of neurology. 2006; 129(Pt 12):3165–72. doi: 10.1093/brain/awl217 PMID: 16921173.

77. Patani R, Balaratnam M, Vora A, Reynolds R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuroepitheliosis and applied neuroepitheliosis. 2007; 33(3):77–87. doi: 10.1111/j.1365-2990.2007.00805.x PMID: 17442065.

78. Di Palma F, Belyantseva IA, Kim HJ, Vogt TF, Kachar B, Noben-Trauth K. Mutations in Mcoln3 associated with deafness and pigmentary defects in von-Waltendorf (Va) mice. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99(23):14994–9. doi: 10.1073/pnas.222425399 PMID: 12403827; PubMed Central PMCID: PMC137533.

79. Guerrini MM, Okamoto K, Komatsu N, Sawa S, Danks L, Penninger JM, et al. Inhibition of the TNF family cytokine RANKL Prevents Autoimmune Inflammation in the Central Nervous System. Immunity. 2015; 43(6):1174–85. doi: 10.1016/j.immuni.2015.10.017 PMID: 26680207.

80. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nature medicine. 2002; 8(5):500–8. doi: 10.1038/nm0502-500 PMID: 11984595.

81. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990; 343(6257):425–79. doi: 10.1038/343425a0 PMID: 1967820.
91. Xu J, Storer PD, Chavis JA, Racke MK, Drew PD. Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. Journal of neuroscience research. 2005; 81(3):403–11. doi: 10.1002/jnr.20518 PMID: 15968640.

92. Zhang-Gandhi CX, Drew PD. Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes. Journal of neuroimmunology. 2007; 183(1–2):50–9. doi: 10.1016/j.jneuroim.2006.11.007 PMID: 17175031; PubMed Central PMCID: PMC2080645.

93. Amin B, Maurer A, Voelter W, Melms A, Kaibacher H. New potential serum biomarkers in multiple sclerosis identified by proteomic strategies. Current medicinal chemistry. 2014; 21(13):1544–56. PMID: 24180278.

94. Abel AM, Schuldt KM, Rajasekaran K, Hwang D, Riese MJ, Rao S, et al. IQGAP1: insights into the function of a molecular puppeteer. Molecular immunology. 2015; 65(2):336–49. doi: 10.1016/j.molimm.2015.02.012 PMID: 25733387; PubMed Central PMCID: PMC4480615.

95. Evans PR, Dudek SM, Hepler JR. Regulator of G Protein Signaling 14: A Molecular Brake on Synaptic Plasticity Linked to Learning and Memory. Progress in molecular biology and translational science. 2015; 133:169–206. doi: 10.1016/bs.pmbts.2015.03.006 PMID: 26123307.

96. Alenghat FJ, Baca QJ, Rubin NT, Pao LI, Matozaki T, Lowell CA, et al. Macrophages require Skap2 and Sirpalpha for integrin-stimulated cytoskeletal rearrangement. Journal of cell science. 2012; 125(Pt 22):5535–45. doi: 10.1242/jcs.111260 PMID: 22976304; PubMed Central PMCID: PMC3561861.

97. Tanabe Y, Shiota A, Kouroku-Murakami Y, Fujita-Jimbo E, Urase K, Takahashi K, et al. Spatial and temporal expression of RA70/Scap2 in the developing neural tube. Neuroscience letters. 2014; 576:1–5. doi: 10.1016/j.neulet.2014.05.013 PMID: 24846415.

98. Shete S, Lau CC, Houlston RS, Claus EB, Barnholtz-Sloan J, Lai R, et al. Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium. Cancer research. 2011; 71(24):7568–75. doi: 10.1158/0008-5472.CAN-11-0019 PMID: 22037877; PubMed Central PMCID: PMC3242820.